Organon

OGN

13.8400.22% ( +0.030 )

Closed: Oct 30, 16:00:00 (EDT)

Current ValuationThe current P/E ratio is 17.06, within the reasonable range, cheaper than 24.14% of the time in the past 1 years, and the industry ranks 30/255, the industry Median -1.04.

17.06xP/E

Stock price$13.84Earnings per share$0.81

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

03876114152

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
RHHBYUSRoche	25.28x	--	$390.54B
RHHVFUSROCHE HOLDINGS AG	26.74x	--	$412.98B
AZNUSAstraZeneca	26.25x	--	$289.48B
GSKUSGSK	17.44x	10.25%	$100.89B
MKKGYUSMerck	26.65x	--	$73.22B
CHGCYUSChugai Pharmaceutical	22.50x	--	$71.27B
UCBJYUSUCB S.A.	23.51x	--	$59.79B
SNYNFUSSanofi	23.93x	--	$109.79B
OTSKYUSOtsuka Pharmaceutical	15.39x	--	$39.86B
HLNUSHaleon	17.62x	1.91%	$38.14B
DSNKYUSDaiichi Sankyo	18.90x	--	$31.75B
LQDAUSLiquidia Tech	29.10x	354.53%	$4.03B
OGNUSOrganon	17.06x	211.11%	$3.63B
ANIPUSANI Pharma	16.24x	51.20%	$1.62B
PAHCUSPhibro Animal Health	15.83x	27.16%	$1.58B
CRONUSCronos	17.37x	944.31%	$1.22B
AMPHUSAmphastar Pharma	15.01x	6.90%	$1.18B
COLLUSCollegium Pharma	16.17x	35.45%	$774.82M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.